top of page

Our Product Pipeline
Relapsed/refractory B-cell lymphomas & B-acute lymphoblastic leukaemia
Currently available for ex-India out-licensing partnerships
2023
Relapsed/refractory Multiple Myeloma ​


2026
Glioblastoma multiforme, Neuroblastoma​


2027
GEJ, Gastric tumours


2028
bottom of page